-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 O3mS/OYYv9Oq5AA4YH+XnpjpHdG7fiMy8ikhMnEPVUvGNCHKWMgK24j5lelIK9Rh
 OeId0D4ht5xhKLUeHkArgw==

<SEC-DOCUMENT>0001157523-11-000311.txt : 20110124
<SEC-HEADER>0001157523-11-000311.hdr.sgml : 20110124
<ACCEPTANCE-DATETIME>20110124171546
ACCESSION NUMBER:		0001157523-11-000311
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20110118
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20110124
DATE AS OF CHANGE:		20110124

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		11544374

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a6583545.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-size: 16pt; font-family: Times New Roman"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt"><b>WASHINGTON,
      D.C. 20549</b></font><br><br><font style="font-size: 16pt; font-family: Times New Roman">FORM
      8-K</font><br><br><br><font style="font-size: 12pt"><b>CURRENT REPORT</b></font><b><font style="font-size: 12pt"><br style="font-size: 12pt"></font><font style="font-size: 12pt">PURSUANT
      TO SECTION 13 OR 15(d) OF THE</font></b><br><font style="font-size: 12pt"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 11pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): </font><font style="font-size: 11pt; font-family: Times New Roman"><b>January
      18, 2011</b></font><br><br><font style="font-size: 16pt"><b>Anika
      Therapeutics, Inc.</b></font><br>(Exact Name of Registrant as Specified
      in Its Charter)
    </p>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Massachusetts</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; width: 34%; white-space: nowrap; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>000-21326</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; width: 33%; white-space: nowrap; text-align: center" valign="bottom">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>04-3145961</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (State or Other Jurisdiction<br>of Incorporation)
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 34%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (Commission File Number)
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 33%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (I.R.S. Employer<br>Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>32 Wiggins Avenue, Bedford, Massachusetts</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 20%; text-align: center" valign="bottom">
          &#160;
        </td>
        <td style="padding-left: 0.0px; padding-right: 0.0px; width: 40%; white-space: nowrap; text-align: center" valign="top">
          <b>01730</b>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="top">
          (Address of Principal Executive Offices)
        </td>
        <td style="padding-left: 0.0px; width: 20%; text-align: center" valign="bottom">

        </td>
        <td style="padding-left: 0.0px; width: 40%; text-align: center" valign="top">
          (Zip Code)
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      Registrant's Telephone Number, Including Area Code: <b>(781) 457-9000</b><br><br><b>N/A</b><br>(Former
      name or former address, if changed since last report)
    </p>
    <p style="text-align: center">

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligations of the registrant under
      any of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
    <p>
      <br>
      <br>

    </p>
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">
    <hr style="width: 100%; color: #000000; text-align: center; height: 1.0 pt">


    <p style="text-align: center">

    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="margin-left: 90.0px; white-space: nowrap">

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 10%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 5.02</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 90%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Departure of Directors or Certain Officers; Election of
            Directors; Appointment of Certain Officers; Compensatory
            Arrangements of Certain Officers.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      (d) &#160;<u>Election of Jeffery S. Thompson to the Board of Directors.</u>
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">
      On January 18, 2011, the Company increased the size of its Board of
      Directors from six to seven members and appointed Jeffery S. Thompson as
      a Class I director of the Company.&#160; Mr. Thompson is Chairman and Chief
      Executive Officer of Advanced Bio-Technologies, Inc., Chairman of
      Woodbury Products, Inc. and is an Operating Partner for HealthEdge
      Investment Partners, LLC, a private equity firm focused exclusively in
      the healthcare industry. For his services as a director of the Company,
      Mr. Thompson will be compensated consistent with the Company's current
      compensation arrangements for its non-employee directors.&#160;&#160;Mr. Thompson
      was not appointed to any committees of the Board of Directors of the
      Company.
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">
      In connection with his appointment to the Board of Directors of the
      Company, on January 18, 2011 Mr. Thompson was awarded restricted stock
      units under the Company's Amended and Restated 2003 Stock Option and
      Incentive Plan.&#160; The award covers an initial grant of 4,196 restricted
      stock units, and a grant of 4,297 restricted stock units as part of his
      annual compensation for service to the Board of Directors.&#160;&#160;Each
      restricted stock unit gives the recipient the right to receive one share
      of the Company&#8217;s common stock, and is valued at $6.98 per unit, the fair
      market value of a share of the Company's common stock on January 18,
      2011.&#160; The restricted stock units vest in four equal yearly installments
      beginning on January 18, 2012.&#160;&#160;A copy of the press release issued by
      the Company on January 20, 2011, announcing the appointment of Mr.
      Thompson to the Board of Directors of the Company is filed as Exhibit
      99.1 hereto and incorporated herein by reference.
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">
      Mr. Thompson was recommended to the Company&#8217;s Board of Directors as an
      unaffiliated independent board designee by Fidia Farmaceutici S.p.A., a
      privately held Italian corporation (&#8220;Fidia&#8221;) holding more than five
      percent of the outstanding shares of the Company&#8217;s common stock,
      pursuant to the terms of that certain Sale and Purchase Agreement, dated
      December 30, 2009, by and between Fidia and the Company (the &#8220;Purchase
      Agreement&#8221;).&#160;&#160;In accordance with the terms of the Purchase Agreement,
      Mr. Thompson was found to be a qualified and mutually acceptable
      director candidate by the Company and Fidia. The above description of
      terms of the Purchase Agreement does not purport to be complete and is
      qualified in its entirety by reference to the full text of the Purchase
      Agreement, which was filed as Exhibit 2.1 to the Company&#8217;s Current
      Report on Form 8-K filed with the Securities and Exchange Commission on
      January 6, 2010 and is incorporated herein by reference.
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">

    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-indent: 30.0px; font-size: 10pt; font-family: Times New Roman">

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 10%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Item 9.01</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 90%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Financial Statements and Exhibits.</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      (d) &#160;<u>Exhibits</u>.
    </p>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 12%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit No.</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 88%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; width: 12%; white-space: nowrap; text-align: left" valign="top">
          99.1
        </td>
        <td style="padding-left: 0.0px; width: 88%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release of Anika Therapeutics, Inc. on January 20, 2011
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font><br>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="width: 50%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" valign="top" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            ANIKA THERAPEUTICS, INC.
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="padding-left: 0.0px; text-align: left" valign="top" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-bottom: 2.0px; padding-left: 0.0px; width: 50%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            January 24, 2011
          </p>
        </td>
        <td style="padding-bottom: 2.0px; padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          By:
        </td>
        <td style="padding-left: 0.0px; width: 45%; border-bottom: solid black 1.0pt; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Kevin W. Quinlan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 45%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Kevin W. Quinlan
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 50%">

        </td>
        <td style="padding-left: 0.0px; width: 5%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 45%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>Chief Financial Officer</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-bottom: 10pt; margin-left: 0pt; text-indent: 0pt; width: 100%; margin-right: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <b>Exhibit Index</b>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-size: 10pt; font-family: Times New Roman; width: 100%" cellspacing="0">
      <tr>
        <td style="padding-left: 0.0px; width: 12%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit No.</b>
          </p>
        </td>
        <td style="padding-left: 0.0px; width: 88%; text-align: center" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="padding-left: 0.0px; padding-right: 0.0px; width: 12%; white-space: nowrap; text-align: left" valign="top">
          99.1
        </td>
        <td style="padding-left: 0.0px; width: 88%; text-align: left" valign="top">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release of Anika Therapeutics, Inc. on January 20, 2011
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6583545ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2011 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Anika
      Therapeutics Appoints Industry Veteran Jeffery S. Thompson to Board of
      Directors</b></font>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Company
      Adds Seat to Board with Addition of Experienced Life Sciences CEO</b></font></i>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--January 20, 2011--Anika Therapeutics,
      Inc. (NASDAQ:ANIK) today announced that it has appointed Jeffery S.
      Thompson, Chairman and Chief Executive Officer of Advanced
      Bio-Technologies, Inc. (ABT), to its Board of Directors. ABT is a
      Georgia-based biopharmaceutical company specializing in the treatment
      and management of scars. With the addition of Mr. Thompson, Anika has
      increased the number of board seats to seven.
    </p>
    <p>
      &#8220;Jeff is a veteran in the life sciences industry with a proven track
      record of executing successful commercial and operating strategies,&#8221;
      said Charles H. Sherwood, Ph.D., president and chief executive officer.
      &#8220;Throughout his career, Jeff has leveraged his knowledge of the
      pharmaceutical industry, strategic planning skills and entrepreneurial
      spirit to effectively optimize operations to help companies meet their
      growth potential. Jeff is an excellent addition to Anika&#8217;s board as we
      work to develop and commercialize a number of exciting products.&#8221;
    </p>
    <p>
      In addition to his role at ABT, Mr. Thompson is an Operating Partner for
      HealthEdge Investment Partners, a private equity firm focused
      exclusively in the healthcare industry. Mr. Thompson also serves as
      Chairman of the Board at Woodbury Products, a New York-based company
      dedicated to the distribution of high quality incontinence and related
      healthcare products. Previously, Mr. Thompson served as Chief Operating
      Officer at Stiefel Laboratories, Inc., where he was also a member of the
      board of directors until the company&#8217;s acquisition by GlaxoSmithKline.
      Prior to becoming Stiefel&#8217;s COO, Thompson served as Stiefel&#8217;s Senior
      Vice President, U.S. Business Services and President of Glades
      Pharmaceuticals. Earlier in his career, Thompson held Sales and Business
      Management positions at Bausch &amp; Lomb Pharmaceuticals and began his
      career at SmithKline Beecham as a Professional Sales Representative. Mr.
      Thompson received his Bachelor&#8217;s degree in General Science after
      completing one year of study in Dental Medicine, both at the University
      of Pittsburgh.
    </p>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing, repair and regeneration. These products are based
      on hyaluronic acid (HA), a naturally occurring, biocompatible polymer
      found throughout the body. Anika&#8217;s products range from orthopedic/joint
      health solutions led by ORTHOVISC<sup>&#174;</sup>, a treatment for
      osteoarthritis of the knee; to surgical aids in the ophthalmic and
      anti-adhesion fields. The company also offers aesthetic dermal fillers
      for the correction of facial wrinkles. Anika&#8217;s Italian subsidiary, Fidia
      Advanced Biopolymers, S.r.l (FAB), provides complementary HA products in
      orthopedic/joint health and anti-adhesion, as well as therapeutics in
      new areas such as advanced wound treatment and ear, nose and throat
      care. FAB&#8217;s regenerative tissue technology advances Anika&#8217;s vision to
      offer therapeutic products that go beyond pain relief to protect and
      restore damaged tissue.
    </p>
    <p>
      <i>The statements made in this press release which are not statements of
      historical fact are forward-looking statements within the meaning of
      Section 27A of the Securities Act of 1933 and Section 21E of the
      Securities Exchange Act of 1934, including, without limitation,
      statements that may be identified by words such as &quot;expectations,&quot;
      &quot;remains,&quot; &quot;focus,&quot; &quot;expected,&quot; &quot;prospective,&quot; &quot;expanding,&quot; &quot;building,&quot;
      &quot;continue,&quot; &quot;progress,&quot; &#8220;plan,&#8221; &quot;efforts,&quot; &quot;hope,&quot; &quot;believe,&quot;
      &quot;objectives,&quot; &quot;opportunities,&quot; &quot;will,&quot; &quot;seek,&quot; &#8220;expect&#8221; and other
      expressions which are predictions of or indicate future events and
      trends and which do not constitute historical matters identify
      forward-looking statements.</i> <i>These statements include, but are not
      limited to, those relating to Anika working to commercialize a number of
      exciting products, and the expected success and contributions of Jeffery
      Thompson.</i> <i>The Company's actual results could differ materially
      from any anticipated future results, performance or achievements
      described in the forward-looking statements as a result of a number of
      factors including: (i) the company's ability to successfully commence
      and/or complete clinical trials of its products on a timely basis or at
      all, obtain clinical data to support a pre-market approval application
      and/or FDA approval, and/or receive FDA or other regulatory approvals of
      its products, or that such approvals will not be obtained in a timely
      manner or without the need for additional clinical trials; (ii) the
      company's research and product development efforts and their relative
      success, including whether the company has any meaningful sales of any
      new products resulting from such efforts; (iii) the cost effectiveness
      and efficiency of our manufacturing operations and production planning;
      (iv) the strength of the economies in which the company operates or will
      be operating, as well as the political stability of any of those
      geographic areas</i> <i>(v) future determinations by the company to
      allocate resources to products and in directions not presently
      contemplated.</i> <i>Certain other factors that might cause the
      company's actual results to differ materially from those in the
      forward-looking statements include those set forth under the headings
      &quot;Business,&quot; &quot;Risk Factors&quot; and &quot;Management's Discussion and Analysis of
      Financial Condition and Results of Operations&quot; in the company's Annual
      Report on Form 10-K for the year ended December 31, 2009, and Form 10-Q
      for the quarter ended September 30, 2010, as well as those described in
      the company's other press releases and SEC filings.</i>
    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D.,
      781-457-9000<br>CEO<br>or<br>Kevin W. Quinlan, 781-457-9000<br>CFO
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
